Mutant Metabolic Enzymes Are at the Origin of Gliomas
- 14 December 2009
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 69 (24) , 9157-9159
- https://doi.org/10.1158/0008-5472.can-09-2650
Abstract
Mutations of the isocitrate dehydrogenase (IDH) metabolic enzymes IDH1 and IDH2 have been found to be frequent and early genetic alterations in astrocytomas and oligodendrogliomas. All mutations identified to date affect a single amino acid located within the isocitrate binding site (R132 of IDH1 and the analogous R172 residue of IDH2). IDH1 and IDH2 mutations define a specific subtype of gliomas and may have significant utility for the diagnosis, prognosis, and treatment of patients with these tumors. [Cancer Res 2009;69(24):9157–9]Keywords
This publication has 22 references indexed in Scilit:
- IDH1andIDH2Mutations in GliomasNew England Journal of Medicine, 2009
- Metabolic Enzymes as Oncogenes or Tumor SuppressorsNew England Journal of Medicine, 2009
- IDH1mutations at residue p.R132 (IDH1R132) occur frequently in high-grade gliomas but not in other solid tumorsHuman Mutation, 2008
- Analysis of the IDH1 codon 132 mutation in brain tumorsActa Neuropathologica, 2008
- An Integrated Genomic Analysis of Human Glioblastoma MultiformeScience, 2008
- Oxygen Sensing by Metazoans: The Central Role of the HIF Hydroxylase PathwayMolecular Cell, 2008
- Genetic Pathways to Primary and Secondary GlioblastomaThe American Journal of Pathology, 2007
- The Consensus Coding Sequences of Human Breast and Colorectal CancersScience, 2006
- Structures of Human Cytosolic NADP-dependent Isocitrate Dehydrogenase Reveal a Novel Self-regulatory Mechanism of ActivityJournal of Biological Chemistry, 2004
- On the Origin of Cancer CellsScience, 1956